Hennion & Walsh Asset Management Inc. Sells 763 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Hennion & Walsh Asset Management Inc. reduced its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 24.6% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,343 shares of the biopharmaceutical company's stock after selling 763 shares during the period. Hennion & Walsh Asset Management Inc.'s holdings in Regeneron Pharmaceuticals were worth $1,486,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Brighton Jones LLC boosted its stake in Regeneron Pharmaceuticals by 261.8% during the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company's stock worth $675,000 after acquiring an additional 686 shares in the last quarter. Avitas Wealth Management LLC boosted its stake in Regeneron Pharmaceuticals by 12.7% during the fourth quarter. Avitas Wealth Management LLC now owns 372 shares of the biopharmaceutical company's stock worth $265,000 after acquiring an additional 42 shares in the last quarter. Tectonic Advisors LLC boosted its stake in Regeneron Pharmaceuticals by 16.6% during the fourth quarter. Tectonic Advisors LLC now owns 830 shares of the biopharmaceutical company's stock worth $591,000 after acquiring an additional 118 shares in the last quarter. Private Wealth Management Group LLC boosted its stake in Regeneron Pharmaceuticals by 260.0% during the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock worth $38,000 after acquiring an additional 39 shares in the last quarter. Finally, Financial Advocates Investment Management bought a new position in Regeneron Pharmaceuticals during the fourth quarter worth $474,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts recently issued reports on REGN shares. UBS Group cut their target price on shares of Regeneron Pharmaceuticals from $633.00 to $560.00 and set a "neutral" rating on the stock in a research note on Thursday. Morgan Stanley lowered their price objective on shares of Regeneron Pharmaceuticals from $958.00 to $755.00 and set an "overweight" rating on the stock in a report on Monday, June 2nd. Citigroup lowered their price objective on shares of Regeneron Pharmaceuticals from $700.00 to $650.00 and set a "buy" rating on the stock in a report on Monday, June 2nd. Truist Financial lowered their price objective on shares of Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating on the stock in a report on Wednesday, April 30th. Finally, Guggenheim restated a "buy" rating on shares of Regeneron Pharmaceuticals in a report on Friday, May 30th. One analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $844.48.

Regeneron Pharmaceuticals Stock Performance

REGN traded up $10.15 during trading on Friday, hitting $493.22. 1,497,861 shares of the company traded hands, compared to its average volume of 860,334. The firm has a market cap of $53.25 billion, a P/E ratio of 12.88, a price-to-earnings-growth ratio of 2.34 and a beta of 0.31. The stock's fifty day moving average is $569.75 and its 200 day moving average is $657.70. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.83 by ($0.61). The company had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. Regeneron Pharmaceuticals's quarterly revenue was down 3.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $9.55 EPS. As a group, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were given a dividend of $0.88 per share. The ex-dividend date of this dividend was Tuesday, May 20th. This represents a $3.52 annualized dividend and a yield of 0.71%. Regeneron Pharmaceuticals's payout ratio is currently 8.96%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.